Amadis and WorldLine Rollout Global Payment Solution with Subway® Restaurants
23.2.2021 13:00:00 EET | Business Wire | Press release
WorldLine, the European market leader in payment and transaction services, and Amadis today announced the completion of its multi-country payment solution rollout with Subway® restaurants. Together WorldLine, Amadis and Subway executed a payments solution to streamline its global payment infrastructure and provide secure, cost-effective and optimized operations for Franchisees.
Subway Franchisees independently own and operate more than 40,000 restaurants in over 100 countries. The use of this new universal payment software makes it easier to operate Subway’s previous international payment infrastructure and provides restaurant owners with a consistent and reliable payment acceptance user-experience. The new framework also allows for a faster deployment of new payment solutions on a global scale, with a projected reduction of testing and certification costs.
“Amadis provided us with clear, proven expertise, ensuring the successful rollout of this global payments project with WorldLine,” said Benoit Lamoureux, payment product owner of Subway® restaurants. “With its unique global perspective in payment software editing, development and standards, along with its reputation for elite global payment deployments, Amadis provided us with assurance that we were addressing key technical issues while implementing this mission-critical initiative.”
“We are pleased to be Subway’s preferred provider of Omni-Channel Payment Solutions,” said Guillaume Pascal, Head of GSV Go To Market / Merchant Services. “WorldLine’s solutions include point of sale system (POS) and e-commerce acceptance as well as payment terminals operating with the nexo retail protocol. An entirely new level of flexibility and efficiency is enabled by implementing the nexo retail protocol and universal payment software that facilitates the connection between card payment infrastructure and the retail POS system.”
“As an expert in global payment standards as well as payment software development, we understand the myriad of system integration and operational issues involved to make large scale, international payment deployments a success,” said Emmanuel Haydont, CEO and co-founder of Amadis. “Global merchants, such as Subway, can realize tremendous efficiencies and cost-savings through global standards and a unified payment framework, while enabling a new level of innovation.”
ABOUT SUBWAY® RESTAURANTS
The Subway restaurant chain continues to evolve the dining experience, offering guests in more than 100 countries quality ingredients and robust flavor combinations with nearly 7 million made-to-order sandwiches created each day. As a Quick Service Restaurant, Subway provides a fresh alternative to traditional fast food offering billions of sandwiches, salad and wrap combinations to guests each day. All approximately 42.500 Subway restaurants are owned and operated by almost 21,000 Franchise Owners who employ hundreds of thousand people around the world, making Subway the world’s largest small business network.
The Subway experience is also delivered online at Subway.com and with the Subcard app.
Subway® is a Registered Trademark of Subway IP LLC. © 2021 Subway IP LLC.
About Worldline
Worldline [Euronext: WLN] is the European leader in the payments and transactional services industry and #4 player worldwide. With its global reach and its commitment to innovation, Worldline is the technology partner of choice for merchants, banks and third-party acquirers as well as public transport operators, government agencies and industrial companies in all sectors. Powered by over 20,000 employees in more than 50 countries, Worldline provides its clients with sustainable, trusted and secure solutions across the payment value chain, fostering their business growth wherever they are. Services offered by Worldline in the areas of Merchant Services; Terminals, Solutions & Services; Financial Services and Mobility & e-Transactional Services include domestic and cross-border commercial acquiring, both in-store and online, highly-secure payment transaction processing, a broad portfolio of payment terminals as well as e-ticketing and digital services in the industrial environment. In 2019 Worldline generated a proforma revenue of 5.3 billion euros. worldline.com
ABOUT AMADIS
Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005297/en/
Contact information
Vivian Shen
+1 437-232-7968
vsh@amadis.ca
Susanne Stöger
+43 1 71701 6524
susanne.stoeger@worldline.com
Hélène Carlander
+33 (0)7 72 25 96 04
helene.carlander@ingenico.com
Ashley Laryea
press@subway.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom